Johnson & Johnson (NYSE: JNJ) released its most recent quarterly results before the markets opened on Tuesday. For the first quarter, the pharmaceutical giant said that it had $2.30 in earnings per share (EPS) and $20.69 billion in revenue, compared with consensus estimates that called for $1.99 in EPS and revenue $19.48 billion. The same period of last year reportedly had EPS of $2.10 on $20.02 billion in revenue.
Consumer Health sales increased 9.2% on an adjusted operational basis to $3.63 billion. This was driven primarily by over-the-counter products, including Tylenol and Motrin analgesics; upper respiratory products, including Zyrtec; digestive health products: and Zarbee’s Naturals.
Pharmaceutical sales increased 10.2% to $11.13 billion. This increase was driven by Stelara (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases; Darzalex (daratumumab), for the treatment of multiple myeloma; Imbruvica (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer; among other drugs.
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined by 4.8%, driven by the estimated net negative impact of the COVID-19 pandemic and the associated deferral of medical procedures to its Surgery, Orthopaedics, Interventional Solutions and Vision businesses.
Looking ahead to the 2020 full year, Johnson & Johnson expects to see EPS in the range of $7.65 to $8.05 and adjusted operational sales between $79.2 billion and $82.2 billion. Consensus estimates are calling for $8.08 in EPS and $79.63 billion in revenue for the year.
Alex Gorsky, board chair and chief executive, commented:
With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic. Johnson & Johnson is built for times like this, and we are leveraging our scientific expertise, operational scale and financial strength in the effort to advance the work on our lead COVID-19 vaccine candidate. We are committed to beginning production at risk imminently and bringing an affordable and accessible vaccine to the public on a not-for-profit basis for emergency pandemic use.
Separately, the board of directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share, compared to the previous rate of $3.80 per share.
Johnson & Johnson stock traded up over 4% on Tuesday, at $146.20 in a 52-week range of $109.16 to $154.50. The consensus price target is $155.41.
24/7 Wall St.Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
